What causes athlete’s foot to worsen?

Worsening of athlete’s foot—medically termed tinea pedis—is typically due to one or more of the following interrelated factors: inadequate or incomplete antifungal treatment, reinfection or re-exposure to dermatophytes (the fungi responsible), compromised skin barrier integrity (e.g., from excessive moisture, maceration, or minor trauma), and underlying host factors that impair immune surveillance or local defense mechanisms. Common behavioral contributors include wearing occlusive footwear for prolonged periods, sharing contaminated items such as towels or shoes, failing to dry feet thoroughly—especially between the toes—and using topical corticosteroids (often mistakenly applied for perceived “inflammation” or “itching”), which can suppress local immunity and promote fungal proliferation—a phenomenon known as tinea incognito.

Medical conditions that predispose individuals to progressive or recurrent tinea pedis include diabetes mellitus (due to impaired neutrophil function, peripheral neuropathy, and microvascular compromise), immunosuppression (e.g., from HIV infection, chronic corticosteroid use, or biologic therapies), and peripheral arterial disease. Additionally, concomitant bacterial superinfection—such as cellulitis or lymphangitis—can mimic or exacerbate clinical severity, particularly when erythema, warmth, swelling, or systemic symptoms like fever develop. In such cases, prompt evaluation for secondary bacterial involvement is essential.

It is important to distinguish true progression of tinea pedis from misdiagnosis—for example, psoriasis, contact dermatitis, or dyshidrotic eczema—which may present with overlapping features like scaling, fissuring, or vesicles but require fundamentally different management strategies. Accurate diagnosis often benefits from potassium hydroxide (KOH) microscopy or fungal culture, especially in recalcitrant or atypical cases. Treatment should be tailored to the clinical subtype (interdigital, moccasin, vesicular, or ulcerative), duration, and patient-specific risk factors, with oral antifungals (e.g., terbinafine or itraconazole) reserved for extensive, chronic, or treatment-refractory disease.